Index

Page numbers in *italics* denote figures, those in **bold** denote tables.

abdominal pain 70
  colorectal carcinoma 215
diverticular disease 249
infectious diarrhea 262
irritable bowel syndrome 223
pancreatitis 306
ABO blood group antigens 143, 264
absolute risk 62
abuse history, and irritable bowel syndrome 227
acetaldheyde dehydrogenase 386–7
adenomatous polyps 214
adenovirus 262
administrative databases 198–9
*Aeromonas* spp. 262, 264
aflatoxin, and hepatocellular carcinoma 351, 385
African populations
  colorectal cancer 214
diarrheal disease 4
age-related frequency
  alcoholic liver disease 337
  colorectal cancer 215
  constipation 240
diverticular disease 250
gallbladder cancer 300
gallstone disease 297
hepatocellular carcinoma 351
infectious diarrhea 263–4
inflammatory bowel disease 275
irritable bowel syndrome 223–4
nonalcoholic fatty liver disease 361
pancreatitis 307
AIDS see HIV/AIDS
alcohol abuse/dependence
  alcoholic liver disease 334
cirrhosis 346
screening tools 333
alcohol consumption 336–7, 336, 347
disease associations
  cholangiocarcinoma 302
  colorectal cancer 387
  constipation 239, 240
diabetic disease 254
esophageal cancer 384–7, 386
gastric cancer 46
hepatocellular carcinoma 351
pancreatitis 307
pattern of 337
alcohol dehydrogenase 386–7
alcoholic liver disease 332–43, 351
clinical features 332, 333, 334
disability 339
disease definition 332
future studies 339
healthcare costs 338–9
hospitalizations 338
incidence and prevalence 333–4, 335
liver transplantations 338
mortality 338
natural history 338
risk factors 334, 336–7
  abuse and dependence 334
  age 337
  alcohol type/quantity 336–7, 336
  frequency of drinking 334
  hepatitis C 337
  pattern of alcohol consumption 337
  years of potential life lost 339
Algeria, celiac disease 187
American Medical Association database 84
American trypanosomiasis 375
Amercas, diarrheal disease 4
anal incontinence 285
analytical studies 79–81, 79, 80
*Anycystoma duodenale* 377–8, 378
antibiotics
  and alcoholic liver disease 325
  and inflammatory bowel disease 277–8
antiinflammatorys, and constipation 241
antidepressants, and constipation 241
antihistamines, and constipation 241
antispasmodics, and constipation 241
appendectomy, and inflammatory bowel disease 277
Argentina, celiac disease 187
*Ascaris lumbricoides* 377
ascertainment bias 21
ascites 346
Asian populations
  colorectal cancer 214
  constipation 237, 238
diarrheal disease 4
  irritable bowel syndrome 226
aspirin
  and constipation 239, 240
  and gastric cancer 148
  and upper GI bleeding 175
astrovirus 262
AUDIT test 333
Australia
  colorectal cancer 214
  constipation 238
  irritable bowel syndrome 225
autoimmune chronic pancreatitis 308
Barrett’s esophagus 124–5
prevalence 123, 124
risk factors 124–5
Bayesian analysis 110–11
Behavioral Risk Factor Surveillance System 84
Beneficiary Identification and Records Locator Subsystem (BIRLS) Death File 86
bias 59, 109
ascertainment 21
case-control studies 30–1, 33
cohort studies 19
follow-up 21
meta-analysis 49, 51
publication 49, 51, 51
RCTs 40, 115
selection 109
spectrum 109
biliary sludge 298
biliary tract cancers 299
biological gradient see dose response
biomarkers 99, 101

INDEX

blinding 41, 44
body fat 395, 396, 397
body mass index (BMI) 395
see also obesity
“brainered” diarrhea 268–9
Brazil, celiac disease 187
CAGE test 333
calcium supplements, and constipation 241
Cameroon, upper GI bleeding 173
Campylobacter spp. 262, 263, 264
Canada
colorectal cancer 214
constipation 238
upper GI bleeding 173, 174, 179
Canadian Institute for Health Information 84
Canadian Registry on Nonvariceal Upper GI Bleeding undergoing Endoscopy (RUGBE) 200–1, 200
cancer see gastrointestinal malignancies; and specific cancer types
candidate gene-disease association studies 104
carbohydrates, and gastric cancer 147
cardiovascular disease, and nonalcoholic fatty liver disease 365–6
case-control studies 30–8
bias 30–1, 33
case selection 31
case study 34–7
checklist 31–4, 37
confounding 33–4
data analysis 34
exposures 33
population-based 80, 80
reverse causality 33
sample size 34
causal relationships 58–9
celiac disease 185–95
description and features 185–6
disability 190
disease definition 186, 186
future studies 191
healthcare costs 190
knowledge gaps 191
mortality 189–90
natural history 189–90, 189
prevalence and incidence 186–7, 187
prevention 190–1
quality of life 190
risk factors 187–9
gender 187
ethics 188
gender 187–8
clostridium difficile 7, 7
cluster randomized trials 117
Cochrane Database 50
Cochrane Q test 52
Cochrane Reviews 50
other diseases 188–9, 188
socioeconomic factors 188
cestodes 378–9
Chagas disease 375
chance 39
chi-square analysis 104
Chicago Health and Aging Project (CHAP) 287
Child-Turcotte-Pugh score 62
childbirth, and fecal incontinence 290–2
children
celiac disease 185–95
disability 190
disease definition 186, 186
future studies 191
healthcare costs 190
knowledge gaps 191
mortality 189–90
natural history 189–90, 189
prevalence and incidence 186–7, 187
prevention 190–1
quality of life 190
risk factors 187–9
gender 187
ethics 188
gender 187–8
coffee, and constipation 239, 240
cohort studies 18–29
bias 19
case study 24–8
checklist 19–24, 27–8
conclusions 23–4
confounding 22
data analysis 22–3, 23
exposures 20
loss to follow-up 21–2
outcomes 20–1
person time 21
population-based 79, 79
sample size 22
study population 19–20
time-varying exposures 22, 26
colonoscopy 197
population-based studies 198–9
quality indicators 197
see also endoscopy
Colonoscopy Reporting and Data System (CO-RADS) 197
colorectal cancer 213–21
case study 24–8
clinical features 215
etiopathogenesis 214–15
global burden 5, 5
incidence 214
mortality 214
nutritional epidemiology 385, 387–9
alcohol 387
red/processed meat 387–8, 388
vitamin D 388–9
primary prevention 217
risk factors 215–17
age and gender 215
colorectal polyps 216
diet and lifestyle 216–17
ethnicity 215
family history and hereditary syndromes 215–16
inflammatory bowel disease 216
screening 217–18
colorectal polyps 216
complex genetic diseases 98, 99
concurrent validity 72
confounding 39
case-control studies 33–4
cohort studies 22, 26
consistency 61
CONSORT guidelines 24, 40, 42, 45
constipation 235–48
children 237
colonic/anorectal physiology 243
disease definition 235–6, 236

406
etiology 243, 243
healthcare costs 242–3
incidence 236
natural history 239, 241
prevalence 236–9, 236–8
quality of life 241–2
risk factors 239, 240–1
representativeness 92
robustness of findings 94
Swedish National Registers 84, 88–90
UK 90–1
USA 85–8
web links 84
see also individual databases
Declaration of Helsinki 115
Danish, esophageal cancer 126
Department of Veterans Affairs (VA) databases 84, 86
descriptive studies 78–9
diabetes mellitus and hepatocellular carcinoma 351
and nonalcoholic fatty liver disease 366–7
and pancreatic cancer 316–17
diagnostic odds ratio (DOR) 107
diagnostic studies 106–12
population choice 109
reference standards 110–11
study design 111
test accuracy 106–9, 107–9
diarrheal disease 11
children 4, 4, 11, 262–72
global burden 4, 4
infectious see infectious diarrhea
diet records 384
dietary assessment instruments 384
dietary factors colorectal cancer 216–17, 385
esophageal cancer 385
gallstone disease 298
gastric cancer 146–8, 385
hepatocellular carcinoma 385
inflammatory bowel disease 278
irritable bowel syndrome 226–7
nonalcoholic fatty liver disease 364–5
pancreatic cancer 385
peptic ulcer 142–3
see also nutritional epidemiology; and
specific dietary components
dietary intake 397–8, 399, 400
Dipylidium caninum 379
direct interviews 77
diabetes alcoholic liver disease 319
celiac disease 190
diverticular disease 257
dyspepsia 165–6
infectious diarrhea 267
inflammatory bowel disease 280
irritable bowel syndrome 228–9
pancreatitis 309
disability-adjusted life years see DALYs
discriminant validity 72
disease etiology 99
diuretics, and constipation 241
diverticular disease 249–61
acute 252–4
mortality 253–4
occurrence 252–3
recurrence rate 253, 257
risk factors 254
complicated 254–7
mortality 255–6
occurrence 254–5, 255
risk factors 256–7
disability 257
disease definition 250
healthcare costs 257
incidence and prevalence 249–51
mortality 251
quality of life 257
risk factors 251–2
diverticulosis see diverticular disease
dose response 61
drug-related disease constipation 239, 240
diverticular disease 256–7
dyspepsia 161–2, 162
gastric cancer 148
inflammatory bowel disease 277–8
pancreatitis 307
upper GI bleeding 175
see also specific drugs/drug types
Duke’s classification 62
duodenal ulcer 138
dyspepsia 158–71
clinical diagnosis 163–4
differential diagnosis 163
disability 165–6
disease definition 158–9
future studies 166
healthcare seeking 165–6
incidence and prevalence 159, 160
mortality 165
natural history 165
prevention 166
quality of life 165–6
red flags 164–5
risk factors 159–63, 161, 162
Rome criteria 158–9
e-mail surveys 78
Eastern Mediterranean region, diarrheal disease 4
Echinococcus spp. 379
Echinostoma spp. 377
economics see healthcare costs
effect measures 23
Egger test 51
Egypt, celiac disease 187
INDEX

electronic health record databases 201–6
EMBASE 50
endoscopic retrograde cholangiopancreatography (ERCP) 201
endoscopic ultrasound (EUS) 201
endoscopy 196–212
administrative databases 198–9
clinical registries 199–201, 200
CORS database 201–6
Entamoeba histolytica 375
environmental factors 99, 99
infectious diarrhea 264–5
obesity 399
peptic ulcer 142
epigeneic studies 101
erosive inflammation 173
erosive reflux esophagitis 122, 122, 123
ers 100–1, 100
Escherichia coli 263, 264
esophageal bleeding 346
esophageal cancer 125–9
international trends 126
nutritional epidemiology 384–7, 385, 386
prevalence 125
risk factors 125–9, 127
and UV exposure 128
ethnic factors
colorectal cancer 215
hepatocellular carcinoma 351–2, 352
infectious diarrhea 264
inflammatory bowel disease 275
irritable bowel syndrome 224, 226
nonalcoholic fatty liver disease 361, 363
pancreatitis 307
European populations
colorectal cancer 214
constipation 237, 238
diarrhal disease 4
irritable bowel syndrome 225
upper GI bleeding 173
see also individual countries
European Prospective Investigation into Cancer and Nutrition (EPIC) 147, 250
evidence hierarchy 59–61, 60
exercise see physical activity exposures
case-control studies 33
cohort studies 20
face validity 72
factorial design 117
Faecalbacterium prausnitzii 279
Fagan’s nomogram 109
false negative (FN) 107
false positive (FP) 107
familial adenomatous polyposis 215, 316
familial diffuse gastric cancer 149
family history
colorectal cancer 215–16
gallstone disease 298
irritable bowel syndrome 227–8
see also genetic factors
family studies 102–3
Fasciola hepatica 376–7
Fasciolopsis buski 377
fecal incontinence 285–95
causes 291
community-based studies 286
future studies 293
health-seeking 292
and institutionalization 292–3
mortality 292–3
onset 289
perineal protective devices 288
prevalence 286–9
quality of life 287–8, 289
risk factors 289–92, 290, 291
severity 287–8, 288, 289
Fecal Incontinence and Constipation Assessment (FICA) 287
fecal microbiome 279
fecal occult blood test (FOBT) 217
fiber and constipation risk 240
and diverticular disease risk 251
and gastric cancer risk 147
Finland
celiac disease 187
esophageal cancer 126
Fisher’s exact test 104
follow-up bias 21
food frequency questionnaires 384, 385
food safety 268
Foodborne Diseases Active Surveillance Network (Food-Net) 265
Forest plots 43, 54, 161, 162
Framingham Risk Score 366
France
esophageal cancer 126
upper GI bleeding 174, 179
funnel plots 51
gallbladder cancer 299–301
epidemiology 299, 300, 301
mortality 299–300
risk factors 300–1, 302–3
gallstone disease 296–9
epidemiology 296–7
and gallbladder cancer 300
and pancreatitis 307
risk factors 297–8, 302–3
stone type 297
underlying conditions 299
“garbage in, garbage out” phenomenon 49
gastric cancer 143–50
clinical outline 143–4
demographic distribution 145
geographic distribution 145
global burden 5
incidence 144–5, 144
nutritional epidemiology 385
risk factors 145–50
secular trends 145
gastric ulcer 138
gastroesophageal reflux disease (GERD) 110, 121–4, 158, 228
global burden 7–8
overlap with other diseases 123
prevalence 122
risk factors 123–4
secular trends 122, 122
gastroesophageal reflux symptoms 122, 122, 123
gastrointestinal disease 11–12
global burden 7–8
hospitalization for 8, 9
gastrointestinal malignancies 11
global burden 4–5, 5
see also specific cancer types
gender-related frequency
celiac disease 187
colorectal cancer 215
constipation 239, 240
diverticular disease 250
gallbladder cancer 300, 300, 301
gallstone disease 298
gastric cancer 144
hepatocellular carcinoma 351, 352
infectious diarrhea 264
inflammatory bowel disease 275
irritable bowel syndrome 223–4
nonalcoholic fatty liver disease 361
pancreatitis 307
genetic epidemiology 98–9, 99
candidate gene-disease association studies 104
clinical and historical studies 101–2
errors 100–1, 100
family studies 102–3
linkage analyses 103–4
principles of 99–100
segregation analyses 103
study design 101–4, 101
INDEX

genetic factors
alcoholic liver disease 337
celiac disease 188
gallstone disease 298
gastric cancer 149–50
infectious diarrhea 264
inflammatory bowel disease 276
nonalcoholic fatty liver disease 363
pancreatic cancer 316
peptic ulcer 143
genomic associations 104
genotyping 101
Geosentinel Surveillance Network 265
Germany
Gastroesophageal reflux disease 124
nonalcoholic fatty liver disease 360, 361
GI Quality Improvement Consortium (GIQuIC) 201
Giardia spp. 262, 263, 264
global death and cancer registries 84–5
HIV/AIDS
diarrhea in 266, 267
and hepatitis C transmission 324
and visceral leishmaniasis 374
Hong Kong, constipation 213
Helicobacter pylori 110, 135–8
clinical microbiology and expression 135–6
distribution of infection 136–7
and dyspepsia 159–61, 161
and gastric cancer 143–6
prevalence 123
risk factors 138
transmission 137–8, 137
and upper GI bleeding 175
Hemoccult Sensa test 218
hepatitis
and cholangiocarcinoma 302
USA 6, 6
see also specific types
hepatitis B 322–31
and cirrhosis 346–7
diagnostic testing 323
disease definition 322
global burden 5–6, 6
incidence 324–5, 325
mortality 328, 329
natural history 327–8
prevalence 326–7
transmission 323–4
hepatitis C 322–31
and alcohol consumption 337
diagnostic testing 323
disease definition 323
global burden 6, 6
incidence 325–6, 325
mortality 328, 329
natural history 327–8
prevalence 326, 327
transmission 324
hepatocellular carcinoma 349–52
disease definition 349
incidence 349–50, 350
mortality 351
prevention 352
risk factors 350–1
survival 351
hepatolithiasis 302
Heterogeneity 52–3
Heterophydae 377
Hiatus hernia 123
Hill, Austin Bradford 61–2
HIV/AIDS
diarrhea in 266, 267
and hepatitis C transmission 324
and visceral leishmaniasis 374
Hong Kong, constipation 238
hookworms 377–8, 378
Hospital Episode Statistics (HES) 90
hospitalization 8, 9, 11–23
see also healthcare utilization
hydrodensitometry 394–5
hygiene hypothesis 278
Hymenolepsis nana 379
importance of association 62
India
celiac disease 187
nonalcoholic fatty liver disease 360, 361
induction time 21
infection
and gallbladder cancer 391
and inflammatory bowel disease 278–9
and irritable bowel syndrome 227
tropical see tropical diseases
infectious diarrhea 262–72
disability 267
future studies 269
healthcare costs 267–8
incidence 263
mortality 266
natural history 266–7
pathogens 263
prevention 268
prognosis 266–7
quality of life 267
risk factors 263–6, 264
age 263–4
environmental 264–5
ethnicity 264
gender 264
geography 264
malnutrition 266
medication, nosocomial infection and comorbid conditions 265–6
seasonality 264
socioeconomic status 264
tropical issues 268–9
inflammatory bowel disease 273–84
clinical features 273
and colorectal cancer 216, 279
disability 280
disease definition 274
future studies 280
and gallbladder disease 299
global burden 8
healthcare costs 280
incidence and prevalence 274–5
mortality 279–80
natural history 279–80
quality of life 280
risk factors 275–9
age and gender 275
antibiotics 277–8
INDEX

inflammatory bowel disease (Continued)
appendectomy 277
diet 278
ethnicity 275
family history 276
fecal microbiome 279
genetics 276
geography 275
hygiene hypothesis 278
infection 278–9
oral contraceptives 277
smoking 276–7
socioeconomic factors 276

International Classification of Disease
(ICD) 251

Internet surveys 78
interviews
direct 77
telephone 78

Iran
ceeliac disease 187
nonalcoholic fatty liver disease 360
Ireland, esophageal cancer 126
iron supplements
and constipation 241
and upper GI bleeding 176
irritable bowel syndrome 222–34
disability and quality of life 228–9
disease definition 222–3
future studies 229–30
healthcare utilization 229
natural history 228
overlap with other diseases 228
post-infectious 267
prevalence and incidence 223, 224, 225, 226
risk factors 223–4, 226–8
abuse 227
age and gender 223–4
diet 226–7
family history 227–8
geography 224
infection 227
psychological 227
race and ethnicity 224, 226
socioeconomic status 226

Israel
ceeliac disease 187
nonalcoholic fatty liver disease 360, 361
upper GI bleeding 173, 174, 179
Italian Dionysos Study 335

Italy
ceeliac disease 187
constipation 237
nonalcoholic fatty liver disease 360
upper GI bleeding 173, 174, 179
Japan
constipation 237
nonalcoholic fatty liver disease 360, 361
Kaplan-Meier curves 23
kappa statistic 51, 71
Kenya, upper GI bleeding 173

Kids Inpatient Database (KID) 87
Korea, nonalcoholic fatty liver disease 360, 361
latency period 21
latent class analysis 110
leishmaniasis 373–5
cutaneous 374
muco-cutaneous 374, 375
visceral 374–5, 374, 375
levels of evidence 59–61, 60
lifestyle factors 22
colorectal cancer 216–17
diverticular disease 256
esophageal cancer 126–7
gallstone disease 298
see also individual lifestyle factors
likelihood ratios 107, 108
Likert scales 70
linkage analysis 103–4
L. monocytogenes 266
literature search 50
liver cancer
global burden 6–7, 7
nutritional epidemiology 385
liver disease
and gallstone disease 299
global burden 5–7, 6, 7
see also specific diseases
liver fluke infestation, and
cholangiocarcinoma 302
liver transplantation 338
loss to follow-up
cohort studies 21–2
RCTs 41, 44
Lynch syndrome 215, 316

McNemar’s test 34
Mallory-Weiss syndrome 173
malnutrition
and infectious diarrhea 266
see also diet
Manning criteria for irritable bowel syndrome 225, 226
meat intake, and gastric cancer 147
Medicaid database 84
Medicare claims files 84, 85–6
Medical Expenditure Panel Survey (MEPS) 84, 87
MEDLINE 50
melaena 172, 177
Mendelian diseases 104
meta-analysis 48–57
bias 49, 51
case study 54–6
checklist 55
heterogeneity 52–3
literature search 50
reading of 50–4
strengths and limitations 49–50
meta-regression 53
metabolic syndrome
and gallstone disease 298
and nonalcoholic fatty liver disease 363–4
see also obesity
5,10-methylenetetrahydrofolate reductase (MTHFR) 150
Mexico
ceeliac disease 187
nonalcoholic fatty liver disease 360
Micronesia/Polynesia, colorectal cancer 214
molecular epidemiology 99, 99
errors 100–1, 100
principles of 99–100
study design 101, 101
mortality
alcoholic liver disease 338
ceeliac disease 189–90
cirrhosis 349
colorectal cancer 214
diverticular disease 251
acute 253–4
complicated 255–6
dyspepsia 165
fetal incontinence 292–3
gallbladder cancer 299–300
hepatocellular carcinoma 351
infectious diarrhea 266
inflammatory bowel disease 279–80
nonalcoholic fatty liver disease 365–7, 366
pancreatic cancer 314
pancreatitis 307
standardized mortality ratio 139
variceal bleeding 178
viral hepatitis 328, 329
muco-cutaneous leishmaniasis 374, 375
multiple endocrine neoplasia 316
Mycobacterium avium paratuberculosis (MAP) 278–9
INDEX

National Ambulatory Care Medical Care Survey (NAMCS) 226, 242
National Colorectal Cancer Roundtable (NCCRT) 197
National Endoscopic Database (NED) 202
National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) 335
National Health and Nutrition Examination Survey see NHANES
National Health and Wellness Survey (NHWS) 242
National Hospital Ambulatory Medical Care Survey (NHAMCS) 242
National Hospital Discharge Survey (NHDS) 84, 87
Nationwide Inpatient Sample (NIS) 87, 198, 252
Necator americanus 377–8, 378
negative likelihood ratio 107, 108
negative predictive value (NPV) 107, 108, 108
Netherlands celiac disease 187
esophageal cancer 126
upper GI bleeding 173, 174, 179
New Zealand, constipation 238
NHANES 84, 287, 288, 290
fecal incontinence 287, 288, 290
obesity 394
NHANES II 224, 226
NHANES III 360
NHANES IV 360
N-nitroso compounds (NOCs), and gastric cancer 147
nonalcoholic fatty liver disease (NAFLD) 357–72
causes 358
clinical diagnosis 358–60, 359
disease associations cardiovascular disease 365–6
type 2 diabetes 366–7
disease definitions 357–8
incidence 361, 362
mortality 365–7, 366
natural history 365–7
prevalence 360–1, 360, 361
prognosis 366
risk factors 361, 363–5, 363
age and gender 361
diet and physical activity 364–5
ethnicity 361, 363
genetics 363
metabolic syndrome 363–4
nonalcoholic steatohepatitis (NASH) 349
nonsteroidal anti-inflammatory drugs see NSAIDs
nonvariceal upper GI bleeding 175, 177–8, 179
norovirus 262, 263, 264
North American Society of Gastroenterology and Nutrition (NASPGHAN) 236
Norway, esophageal cancer 126
nosocomial infection 265–6
NSAIDs and constipation 239, 240
and diverticular disease 256–7
and dyspepsia 161–2, 162
and gastric cancer 148
and upper GI bleeding 175
number needed to harm (NNH) 63–4
number needed to treat (NNT) 63–4
nutritional epidemiology of cancer 383–93, 385
dietary assessment instruments 384, 385
measurement error correction 389–90
statistical adjustment for total energy 389
see also dietary factors; and individual cancer types
obyesity 394–404
consequences of 399, 401
definition 394–5
determinants of 397–9
dietary intake 397–8, 399, 400
environment 399
physical activity 399
disease associations alcoholic liver disease 337
and colorectal cancer 217
constipation 240
duodenal disease 254, 256
gallbladder cancer 300–1
gallstone disease 298
hepatocellular carcinoma 350
pancreatic cancer 316
international context 397, 398
prevalence and trends 395–7, 396, 397, 398
obesity paradox 401
objective measures 20
obstetric injury 290–2
obstructive chronic pancreatitis 308
Office for National Statistics for England and Wales 90
opiates and constipation 240
and diverticular disease 256–7
Opiostachys felineus 376
Opiostachys viverrini 302, 376
oral contraceptives, and inflammatory bowel disease 277
outcomes cohort studies 20–1, 25–6
RCTs 42, 44
Oxford Centre for Evidence-Based Medicine 59
pancreatic cancer 313–21
disease definition 313
incidence and prevalence 313–15, 314, 315
mortality 314
nutritional epidemiology 385
risk factors 315–17
pancreatitis 306–12
acute 306–8
demographics and risk factors 307
disease definition 306
future studies 308
healthcare costs 307
incidence and prevalence 306–7
natural history and mortality 307
chronic 308–10
autoimmune 308
calculating 308
demographics and presentation 309
disability and quality of life 309
disease definition 306
epidemiology 308–9
future studies 310
natural history 309
obstructive 308
prevention 309–10
risk factors 309
and pancreatic cancer 315–16
patient comorbidity 93–4
pedigrees 103, 104
peptic ulcer disease 138–43, 175
in Asian populations 143
diet 142–3
distribution of cases 141
and diet 142–3
distribution of cases 141
and diet 142–3
distribution of cases 141
and diet 142–3
distribution of cases 141
genetic factors 143
healthcare perspective 140–1, 141
healthcare utilization 141
prevalence 139, 140–1
psychological factors 143
risk factors 142
secural trends 139–40, 140
see also Helicobacter pylori
perianal protective devices 288
permuted-block stratified randomization 114
personal identity numbers (PINs) 91
Peutz-Jeghers syndrome 316
INDEX

phenotyping 101
physical activity
   and constipation risk 240
   and diverticular disease risk 256
   and nonalcoholic fatty liver disease risk
   364–5
   and obesity 399
PICO 50
pilot studies 77
plausibility 61
Plesiomona spp. 262
Poisson regression 23
polyps
   adenomatous 214
   colorectal 216
population attributable fraction 64
population-based studies 75–82
   aims 76
   data collection 77–81
   analytical 79–81, 79, 80
   descriptive 78–9
   engagement of contributors 76
   location 76
   sampling 76–7
portal hypertension 346
positive likelihood ratio 107, 108
positive predictive value (PPV) 61, 107,
108, 108
postal surveys 77
prevalence studies 80–1, 80
primary sclerosing cholangitis 302
PRISMA statement 50
proton pump inhibitors 175–6
protozoal diseases 375–6
publication bias 49, 51, 51
QALYs 63
quality of life
   celiac disease 190
   constipation 241–2
   diverticular disease 257
   dyspepsia 165–6
   fecal incontinence 287–8, 289
   infectious diarrhea 266–7
   inflammatory bowel disease 280
   irritable bowel syndrome 228–9
   pancreatitis 309
   quality-adjusted life years see QALYs
questionnaires 67–74
   development 68–70, 68
   feasibility 70–1
   need for 67–8
   population-based studies 77
   question choice 69–70
   reliability 71
scope 69
survey method 69
use of 72–3
validation 68, 70–2
random errors 100
randomization 114
randomized controlled trials (RCTs)
   39–47, 59, 113–18
   allocation sequence 40–1, 43–4
   bias 40, 115
   blinding 41, 44
   case study 43–5
   checklist 40–3, 45–6
   CONSORT statement 42, 45
   data analysis 42, 44–5
   interventions 41–2, 44
   key features 114–15
   loss to follow-up 41, 44
   outcomes 42, 44
   pitfalls 43
   study population 41, 44
   types of 117
   RCTs see randomized controlled trials
Read and Oxford Medical Information
   Systems (OXMIS) codes 93
red meat consumption
   and colorectal cancer 387–8, 388
   and diverticular disease 252
reference standards 110–11
relative risk 62
research
   databases 50, 83–97
   genetic/molecular 98–105
   population-based studies 75–82
   questionnaires 67–74
   reverse causality 33, 59
   response
   sensitivity 107–8, 107
   specificity 61, 107–8, 107
   spectrum bias 109
   spironolactone, and upper GI bleeding
   176
socioeconomic factors
   celiac disease 188
   and constipation risk 240–1
   and diverticular disease 252, 256
   gastric cancer 146
   inflammatory bowel disease 276–7
   pancreatic cancer 315
   South America, colorectal cancer 214
   Spain, upper GI bleeding 174
   specificity 61, 107–8, 107
   standardized mortality ratio (SMR) 139
   statistical calculators, publicly available 93
   stomach cancer see gastric cancer
   stratified random sample 77
   strength of association 61
   study design
   genetic/molecular epidemiology 101–4,
   101
   and test performance 111
INDEX

study population
cohort studies 19–20
RCTs 41, 44
summary receiver operator curve (sROC) 107
surveys 75–82
Sweden
constipation 237
esophageal cancer 126
Swedish Mammography Cohort 252
Swedish National Registers 84, 88–90
Cancer Register 88
Cause of Death Register 88
Hospital Discharge Register 89
Medical Birth Register 89
Multigeneration Register 89
Outpatient Register 89
Swedish Conscription Register 88
Total Population Register 88
systematic errors 100
systematic random sample 76
systematic reviews 48–57
Systematized Nomenclature of Medicine (SNOMED) 93
t-test 34
*Taenia saginata* 378
*Taenia solium* 379
Taiwan, nonalcoholic fatty liver disease 360
telephone interviews 78
temporality 61
test performance 106–9
likelihood ratios 107, 108
and population choice 109
positive/negative predictive values 107, 108, 109
sensitivity and specificity 107–8, 107
single measures 108–9, 109
and study design 111
time-varying exposures 22, 26
Togo, upper GI bleeding 173
trematodes 376–7
tropical diseases 373–82
cestodes 378–9
nematodes 377–8
protozoa 373–6
trematodes 376–7
*Trypanosoma cruzi* 375
*Trypanosoma cruzi* diseases 373–5
Tunisia, celiac disease 187
Turkey, constipation 237
twenty-four-hour recall interview 384
twin studies 102–3
UK
celiac disease 187
databases 90–1
esophageal cancer 126
irritable bowel syndrome 225
lower GI bleeding 173, 174, 179
ulcerative colitis see inflammatory bowel disease
ulcers 173
duodenal 138
gastric 138
peptic 138–43, 175
ultraviolet radiation, and esophageal cancer 128
United Kingdom Clinical Practice Research Datalink 84
United Network for Organ Sharing 84
upper gastrointestinal bleeding 172–84
comorbidity 176
diagnosis 173
*H. pylori* 175
incidence 174–5, 174
medication-induced 175–6
nonvariceal 175, 177–8, 179
risk factors 175–6
variceal 172, 173, 176–7, 178–9, 178
US Multi-Society Task Force on Colorectal Cancer (MSTF-CRC) 196–7
USA
celiac disease 187
colorectal cancer 214
constipation 237, 238
databases 85–8
irritable bowel syndrome 225
nonalcoholic fatty liver disease 360, 361
upper GI bleeding 173, 174, 179
VA Outpatient Care File 86
VA Patient Treatment File 86
VA-Medicare linked database 86
validity 72
variceal bleeding 172, 173, 176–7, 178–9, 178
healthcare costs 178–9
mortality 178
*Vibrio* spp. 264
viral hepatitis see hepatitis
visceral leishmaniasis 374–5, 374, 374
vitamin A, and gastric cancer 147
vitamin C, and peptic ulcer disease 143, 147
vitamin D, and colorectal cancer 388–9
vitamin E, and gastric cancer 147
von Hippel-Lindau syndrome 316
waist circumference 395, 396
washout period 117
weight loss, and gallstone disease 298
Western Pacific, diarrheal disease 4
WHO 3, 84, 262
mortality database 84
World Health Organization see WHO
Yersinia spp. 262, 264
Zambia, upper GI bleeding 173

413